NeoPredics Announces Prof. Stefan Verlohren as Chairman of Medical and Scientific Advisory Board

FORT LAUDERDALE, FLORIDA / ACCESSWIRE / January 2, 2025 / NeoPredics AG Switzerland, together with its subsidiaries NeoPredics AG Germany and NeoPredics USA Inc., a leader in predictive analytics and clinical decision support for maternal and neonatal health, is proud to announce that Prof. Stefan Verlohren will join the company as Chairman of the Medical and Scientific Advisory Board, effective January 1, 2025.

Prof. Verlohren is a highly distinguished Professor of Obstetrics and the Chairman and Director of the Department of Obstetrics and Fetal Medicine at University Medical Center Hamburg-Eppendorf (UKE), Germany. With over two decades of experience in maternal-fetal medicine and an extensive background in clinical innovation, he has dedicated his career to advancing care for women and newborns.

Thorsten Waloschek, CEO of NeoPredics, shared his enthusiasm about the appointment:

“Prof. Verlohren’s leadership and expertise in maternal-fetal medicine align perfectly with NeoPredics’ mission to transform outcomes for women and newborns. His guidance will strengthen our commitment to predictive technologies that ensure timely and precise interventions in critical moments of care.”

Prof. Verlohren’s addition to NeoPredics’ advisory board reflects the company’s strategy to partner with global leaders in healthcare to advance NeoPredics’ vision. His experience with innovative projects, such as the PreFree initiative, and his significant contributions to the field of preeclampsia and hypertensive pregnancy disorders further solidify NeoPredics’ position at the forefront of maternal and neonatal health solutions.

NeoPredics remains committed to redefining healthcare for women and children through cutting-edge predictive algorithms. The addition of Prof. Verlohren to the medical team of the two founders Prof. Sven Wellmann and Prof. Marc Pfister, is a significant milestone in this journey.

Contact Information

Lia Butler
Director of Sales & Marketing, US
lia.butler@neopredics.com
6092736911

SOURCE: NeoPredics

View the original press release on accesswire.com

Staff

Recent Posts

Restart Life Sciences Announces Closing First Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

10 minutes ago

TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

11 minutes ago

Correction to MyndTec Inc. Press Release Issued December 3, 2025 Regarding Non-Brokered Private Placement

Mississauga, Ontario--(Newsfile Corp. - December 5, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), announced…

11 minutes ago

Atropos Health Expands Oncology Precision Medicine Capabilities with Publication of New AI Algorithms for Rare Disease and Integration of ASCO Guidelines

Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…

5 hours ago

USF and Old Dominion to Play in the 2025 StaffDNA Cure Bowl

PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…

5 hours ago

The Dot Corp Expands Services With New Promotional Products & Apparel Division

IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…

5 hours ago